Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo Nordisk has become a global sensation with its popular weight loss drugs like Ozempic and Wegovy. On Wednesday, the Danish multinational pharmaceutical company announced that it would begin ...

NEW YORK, NY / ACCESS Newswire / March 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...